Escalating anti-tumour necrosis factor exposure with reductions in surgical resection rates in paediatric inflammatory bowel disease: an 18-year real-world population-based cohort study - Quiz - MDSpire

Escalating anti-tumour necrosis factor exposure with reductions in surgical resection rates in paediatric inflammatory bowel disease: an 18-year real-world population-based cohort study

  • By

  • Zachary Green

  • Myrna Nicholas

  • Stephanie Vuijk

  • Mike Stanton

  • Christopher Bakewell

  • Tracy Coelho

  • Akshay Batra

  • Nadeem A Afzal

  • Sarah Ennis

  • Robert Mark Beattie

  • James Ashton

  • June 24, 2026

  • 0 min

Share

Original Source(s)

Escalating anti-tumour necrosis factor exposure with reductions in surgical resection rates in paediatric inflammatory bowel disease: an 18-year real-world population-based cohort study

  • by Zachary Green, Myrna Nicholas, Stephanie Vuijk, Mike Stanton, Christopher Bakewell, Tracy Coelho, Akshay Batra, Nadeem A Afzal, Sarah Ennis, Robert Mark Beattie, James Ashton

  • June 24, 2026

Related Content

Correction: Incidence of Clostridium difficile infection and enteric pathogens in children with inflammatory bowel disease presenting with disease exacerbation

3 Innovations Revolutionizing IBD Treatment

Keck Medicine of USC gastroenterologist Florence-Damilola (Damie) Odufalu, MD, shares how recent advances in inflammatory bowel disease treatment are changing the lives of patients.

  • by

  • May 26, 2026

  • 5 min
Integrative single-cell transcriptomics and mendelian randomization identifies BTN3A2 as a shared protective factor in Behçet’s disease and inflammatory bowel disease